Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of MK-2870 and Chemotherapy for Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of lung cancer known as Non-small Cell Lung Cancer (NSCLC) that has a specific mutation called EGFR-mutated. The study is comparing a new treatment called MK-2870 with a standard chemotherapy treatment known as platinum-based doublet chemotherapy. The chemotherapy includes drugs like carboplatin and pemetrexed, which are commonly used to treat this type of cancer. The purpose of the study is to see how well MK-2870 works compared to the standard chemotherapy in terms of how long patients live without the cancer getting worse and overall survival.

Participants in the study will receive either MK-2870 or the standard chemotherapy. MK-2870 is given as an intravenous infusion, which means it is administered directly into the bloodstream through a vein. The study will last for a period of up to 72 weeks, during which the effects of the treatments will be monitored. The study will also look at other aspects such as the response rate to the treatment, the duration of the response, and changes in quality of life related to symptoms like cough and chest pain.

In addition to MK-2870 and the chemotherapy drugs, other medications may be used in the study, including H2-Receptor antagonists, glucocorticoids, antihistamines, and a combination of buclizine hydrochloride, paracetamol, and codeine phosphate. These medications are used to manage side effects or other conditions that may arise during the treatment. The study aims to provide valuable information on the effectiveness and safety of MK-2870 compared to the current standard treatment for patients with this type of lung cancer.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, a diagnosis of advanced non-small cell lung cancer (NSCLC) with specific genetic mutations is confirmed.

    Eligibility is determined based on recovery from previous treatments, viral infection status, and overall health condition.

  2. Step 2

    Treatment assignment

    Participants are randomly assigned to receive either MK-2870 or a combination of chemotherapy drugs known as platinum doublets.

    The objective is to compare the effectiveness of MK-2870 with the chemotherapy regimen.

  3. Step 3

    Treatment administration

    For those receiving MK-2870, the medication is administered as a powder for solution for injection through an intravenous infusion.

    Participants receiving chemotherapy will be given a combination of pemetrexed and carboplatin through intravenous infusion.

  4. Step 4

    Monitoring and assessments

    Regular assessments are conducted to monitor progression-free survival and overall survival.

    Additional evaluations include response rate, duration of response, and changes in quality of life indicators such as global health status, breathing difficulties, cough, and chest pain.

  5. Step 5

    Adverse events monitoring

    Participants are monitored for any adverse events that may occur during the study.

    The number of participants experiencing adverse events and those discontinuing treatment due to adverse events are recorded.

  6. Step 6

    Study completion

    The study is estimated to conclude by June 14, 2030.

    Final assessments will be conducted to evaluate the long-term outcomes of the treatments.

Who can join the trial?

7 criteria

  • You must have a confirmed diagnosis of advanced-stage **non-small cell lung cancer (NSCLC)**, which is a type of lung cancer.
  • If you had side effects from previous cancer treatments, they must have improved to a mild level or returned to how they were before treatment.
  • If you have **Hepatitis B**, you can participate if you have been on antiviral treatment for at least 4 weeks and the virus is not detectable in your blood.
  • If you have had **Hepatitis C**, you can participate if the virus is not detectable in your blood.
  • If you have **HIV**, you can participate if your HIV is well controlled with medication.
  • You should have a life expectancy of at least 3 months.
  • Both men and women can participate.

Who cannot join the trial?

3 criteria

  • Patients with a different type of lung cancer that is not Non-small Cell Lung Cancer (NSCLC) with an EGFR mutation cannot participate. EGFR mutation refers to a change in a specific gene that can affect how cancer grows.
  • Patients who are not within the specified age range for the study cannot participate. The study is open to certain age groups only.
  • Patients who are part of a vulnerable population, which means they might need special protection or care, are not included in this study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • MK-2870

    is an investigational medication being studied for its effectiveness in treating advanced non-squamous non-small cell lung cancer (NSCLC) in patients who have specific genetic mutations (EGFR mutations) and have not responded to previous treatments. This medication is being compared to standard chemotherapy treatments to see if it can help patients live longer or slow down the progression of their cancer.

  • Platinum-based doublet chemotherapy

    is a standard treatment for advanced non-squamous non-small cell lung cancer. It involves using two chemotherapy drugs, one of which is a platinum compound, to try to stop the cancer cells from growing and dividing. This treatment is being used as a comparison to see how well MK-2870 works in treating this type of lung cancer.

What is already known about the treatment

MK-2870 – This medication is administered orally and is currently being studied in clinical trials for its effectiveness in treating advanced non-squamous non-small cell lung cancer (NSCLC) with EGFR mutations. It is in the experimental phase and is not yet widely available in medical practice. The main therapeutic indication is for patients who have progressed after treatment with EGFR tyrosine kinase inhibitors. MK-2870 works by targeting specific proteins involved in cancer cell growth, thereby inhibiting tumor progression. It is classified as a targeted cancer therapy, specifically an EGFR inhibitor.

Investigated diseases

Non-small Cell Lung Cancer (NSCLC), EGFR-mutated – This is a type of lung cancer characterized by mutations in the epidermal growth factor receptor (EGFR) gene. It is the most common form of lung cancer, accounting for a significant majority of cases. The disease typically begins in the cells lining the lungs and can spread to other parts of the body. EGFR mutations lead to uncontrolled cell growth and division, contributing to tumor development. As the cancer progresses, it may cause symptoms such as persistent cough, chest pain, and difficulty breathing. The progression of the disease can vary, with some cases advancing more rapidly than others.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-504910-31-00Protocol codeMK-2870-009Estimated enrolment562 patientsSponsorMerck Sharp & Dohme LLC

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).